Publications du CNR en 2025

Gerussi, V., Petersen, T., Bonnet, I., Aubry, A., Bachir, M., Gyde, E., Morel, F., Poignon, C., Rached, B., Pourcher, V., Rioux, C., Vallois, D., Veziris, N., Robert, J. and Guglielmetti, L. (2025). Evaluation of High-Dose Isoniazid in Multidrug-Resistant Tuberculosis Treatment. Emerg Infect Dis 31, http://doi.org/10.3201/eid3103.241473.

Guglielmetti, L., Khan, U., Velásquez, G. E., Gouillou, M., Abubakirov, A., Baudin, E., Berikova, E., Berry, C., Bonnet, M., Cellamare, M., Chavan, V., Cox, V., Dakenova, Z., De Jong, B. C., Ferlazzo, G., Karabayev, A., Kirakosyan, O., Kiria, N., Kunda, M., Lachenal, N., Lecca, L., McIlleron, H., Motta, I., Toscano, S. M., Mushtaque, H., Nahid, P., Oyewusi, L., Panda, S., Patil, S., Phillips, P. P. J., Ruiz, J., Salahuddin, N., Garavito, E. S., Seung, K. J., Ticona, E., Trippa, L., Vasquez, D. E. V., Wasserman, S., Rich, M. L., Varaine, F. and Mitnick, C. D. (2025). Oral Regimens for Rifampin-Resistant, Fluoroquinolone-Susceptible Tuberculosis. N Engl J Med 392, 468–482, http://doi.org/10.1056/NEJMoa2400327.

Guthmann, J.-P., Robert, J., Viriot, D. and Parent Du Chatelet, I. (2025). Incidence, severity and treatment outcome of tuberculosis in the era of the COVID-19 pandemic, France, 2018–2023. Journal of Epidemiology and Population Health 73, 202795, http://doi.org/10.1016/j.jeph.2024.202795.